Overview

The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis

Status:
Unknown status

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

In a double-blind, placebo-controlled, parallel group trial, recombinant human erythropoietin (rhEPO) (48000 IU) treatment or placebo will be administered weekly i.v. for 24 weeks: weekly for 12 weeks and bi-weekly for 12 weeks. Methylprednisolone (MP) 1 g i.v. will be administered before the first and second EPO/placebo administration. The 24-week treatment period will be followed by a 24-week observation period.

Phase:

Phase 2

Details

Lead Sponsor:

Rigshospitalet, Denmark

Collaborator:

Danish Research Centre for Magnetic Resonance

Treatments:

Epoetin Alfa